Drugs / leteprinim
leteprinim
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000180 | ? → Jun 2005 | amnestic disorder | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00041795 | Jan 2002 → ? | chemotherapy-induced neuropathy | NeoTherapeutics | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | leteprinim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00041795 ↗ |
| Known as | AIT-082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000180 ↗ |
| Known as | leteprinim potassium | “leteprinim potassium (Neotrofin)” NCT00041795 ↗ |
| Known as | Leteprinim potassium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104345 ↗ |
| Known as | Neotrofin | “A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin, NeoTherapeutics) was conducted in mild Alzheimer's...” PMID 12770610 ↗ Jun 20031“leteprinim potassium (Neotrofin)” NCT00041795 ↗ |
| Modality | Small molecule | “AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve...” NCT00000180 ↗ |
| Route | Oral | “Patients received an oral dose of AIT-082 or placebo daily for one week.” PMID 12770610 ↗ Jun 2003 |